Introduction
ALL has a high incidence in the paediatric age groups. Toddlers are at highest risk for ALL, the incidence declines steeply from 4 years onwards. Annual incidence rate per million in the US lies at 77 at the age of 2 years, at 14 years the incidence is 17 [1] . In 1994 55% of the 166 Dutch ALL cases were below 20 years of age. Only 8% had ages between 10 and 19 years [2] . In the UK, with an estimated number of 605 cases per year, higher percentages of 67% and 18% are reported, respectively [3] .
The high frequency of ALL in children and the fact that during the last 30 years ALL has become a curable disease in most children, are some of the major causes for the success in paediatric oncology [4, 5] . However, during the last decade, assessing 10-year survival rates instead of five-year survival rates, further progress might have been absent [6] . Also in children > 10 years, suffering from ALL improvements were less if compared with the younger age groups [7] . Similarly, treatment results have improved in adults with ALL, but they are not that spectacular if compared with children [8] [9] [10] . In adults, especially in those above the age of 35 years, the CR-rate and ultimate prognosis for ALL is still poor. In childhood cure rates of 65%-80% are reached, in adults cure rates of 25%-40% are still reported [11, 12] . However, using protocols similar to those for of younger ages, young adults do have better EFS rates (60% is reported), which are comparable to the results of children with ages of 10-15 years [11] .
In most centres, depending on the physician (a paediatrician or a haematologist) patients with ALL with ages ranging from 10 to 20 years are treated by different protocols. For instance many haematologist advocate for adults with ALL allogeneic bone marrow transplantation, in most children only chemotherapy is found to be appropriate. Additionally, in literature it is stated that outcome of patients, similarly treated either by paediatricians or by haematologist, is better in patients treated in a paediatric department. It is speculated that this difference may reflect the different attitudes of both disciplines towards this specific age group; i.e., adolescents are regarded by the paediatricians to have a high relapse risk, whereas haematologists regard them as good risk patients [9] . As a result of these mentioned points data for adolescents are scattered over various reports in literature and are hard to compare [11] .
Although it is easy to assume that ALL cases in the cohort between 10 and 20 years, are a subgroup, which clinically and biologically present in between the younger and adult cohorts. In this review at least some data, will illustrate that the mentioned assumption is not correct.
Clinical presentation
It was already indicated that teenagers are both treated according to protocols of study groups for children as well as for adults. From the diverse reports in literature the following points can be deduced. Similar to adults, there is an increased incidence of T-cell immunophenotype, L2 morphologic characteristics, high serum LDH, higher hemoglobin level and DNA-index <1.16 and chromosomal translocations. A lower incidence of hyperdiploidy is noted in adolescents with ALL [11, 13, 14] . Although all these features are linked with a T-cell phenotype, also after exclusion of the T-ALL cases, the mentioned characteristics are still significantly more frequently noted in adolescents [5, 13] . In respect to risk factors related to ultimate outcome a major factor, as compared to children < 10 years of age, the presence of leukocyte counts over 50 x 10 9 /l is more frequent. A decreased survival, comparing the age groups between 10 and 14 years versus those between 15 and 18 years, was not only related with an age > 15 years, but also with L2 morphology (both as independent factors) [5, 7] . Abnormalities found on karyotyping and expression of CD3 on the membrane are also related to survival differences [15] . Immunophenotype did not influence outcome. However, considering the data of Uckun et al. precise determination of immunephenotype subtypes has indicated that pro-T-cell ALL is not only more frequent in children over 10 years of age, but is also related with a worse prognosis [16, 17] . Since children and adults are treated in the UK according to similar protocols Chessells et al. were able to give comparable details for children and adults as well. However in adults protocol compliance was lower, i.e., 2.5% protocol violations in the pediatric studies versus 22% in the adult studies. Comparison of the various age groups has shown that patients with ages between 10 and 20 years have the highest numbers of WBC, enlargement of liver and spleen, T-immunophenotype in comparison with the younger and older age groups. In each age group of ALL patients there is a male predominance, however it is most prominent in the ages 15 to 19 years. Enlargement of lymphnodes is more frequent in the younger age groups [3] . An outline of the most significant findings of Chessells et al. are given in Table 1 .
Genetics
In the large majority of ALL cases cytogenetic abnormalities are found. They play a central role in the development of leukaemia. There are strong associations between certain chromosomal abnormalities and morphological and immunophenotypical characteristics of the leukaemia. For instance the t(8;14) occurs in mature B-cell leukemia with L3 morphology. An other important aspect of the karyotypic changes is that they provide important information on the prognosis, independent of other factors such as age and WBC. There are major discrepancies in genotypic changes comparing adults and children. These differences, as presented by Pui et al. [12] , are summarised in Table 2 . Also the survival data are closely linked to these genetic changes; see Table 3 [12], However, there are only a limited number of reports focussing on the adolescent group of patients [18] . In children the best prognosis is related with a hyperdiploid karyotype [19] . This karyorype is most frequent in the younger age group < 10 years, and has in general relatively low WBC's at diagnosis and CD10 positivity [20] . The second genetic change most often observed in children is TEL-AML1 fusion, on a karyogram seen as t(12;21) [12, 21] , This anomaly is closely linked with hyperdiploidy (>50 chromosomes) and low leukocyte counts. Presence of TEL/AML1 fusion in lymphoblasts is considered to be a sign of good prognosis, however, above the age of 10 years TEL/AML1 fusion is seldomly seen [12, 21] . Borkhardt et al. showed positivity in 12% in the age groups of 10-15 years versus 31% in the younger age groups. In that study a significant better survival is noted in TEL/AML1 positive cases, but age above six year, immunephenotyping and WBC, were of more importance [22] . Since t(12;21) and hyperdiploidy are related with a good prognosis, the lower outcome in adolescents may be partially explained by the paucity of hyperdiploid and TEL-AML1 positive cases.
Although the frequency of hyperdiploidy in adoles-cents is lower, the scarcely noted cases with tetraploidy are seen more often at an older age. The fact that tetraploidy is linked with a T-cell immunophenotype is compatible with this finding [23, 24] . Fortunately ALL in childhood has a low percentage of Philadelphia chromosome positivity. Adults have higher rates of Philadelphia positivity. However this chromosome anomaly is mostly seen in adults over the age of 50 (up to 43.8% is reported). Although the frequency for 15-19-year-old patients was found to be 10.3%, more recent data mention figures of only 3.5%. For 10-14-year-olds the frequency is similar. Under the age of 10 years a frequency below 1.5% is reported [3] . Recently the data of 10 cooperative paediatric trials were pooled for Philadelphia+ cases; 38% of cases were above the age of 10 years, although only 8% were ^ 15 years. A leukocyte count > 100,000 (35% of cases), common phenotype (97%) and poor response to initial treatment (15% no CR after induction therapy) was noted. EFS was 35% at five years. A better outcome was related with a younger age, good response to corticosteroid treatment and a low initial cell count. Analysis of the chromosome breakpoints in case of Philadelphia positivity, indicated that M-bcr+ cases did not fare better [25] . However, considering the incidence of Ph+ ALL, these data cannot explain the poorer survival for the whole group 10-19-year-old patients [26] .
In infants prognosis is strongly related to the existence of a rearrangement of the MLL-gene at the Ilq23 locus. In adults the frequency is about 9% in the age groups > 40 years [3, 27] . Since the frequency in adolescence is very low; 0%-1.7% is reported, this translocation does not influence outcome in this age category [3, 27] . Prognosis in case of these translocations involving Ilq23 is poor, although the data are based on a limited number of patients.
There has been a debate in literature on the prognositic value of t(l;19). Although only noted in a about 3%-6% of ALL cases, t(l;19) is noted twice as often in the age group above 10 years. Blasts mostly have the pre-B-immunophenotype (clg + and slg~). Pre-B-ALL with t(l;19) is linked with higher leucocyte counts and the black race. Crist et al. state that t(l;19) in children is a risk factor. Exclusion of children with this translocation conferred the prognostic value of pre-B-immunophenotype from a negative into a positive factor [28] . Unfortunately no ages are mentioned in the manuscript. Others state that in children EFS is similar to non-t(l;19) cases. Further delineation of t(l; 19) showed that in the 25% of cases with a balanced t(l;19) the prognosis is worse; four-year EFS 40% versus 80% for the unbalanced cases. At least in the age group <21 years, correction for age did not influence this observation [29] . It has been demonstrated that the frequency of a balanced form of t(l;19) is more frequent in adults. This might be one of the explanations for the poorer in outcome in the patient groups with higher ages [12, 30] .
In the last decade PCR-based determination of the level of minimal residual disease during initial treatment has shown to be one of the strongest predictors on ultimate outcome, i.e., a rapid decline of tumour burden is seen in patient with an excellent prognosis [31, 32] . No specific data exist for adolescents.
Outcome
Although the age of 10 years is generally accepted to be the limit above which ALL does not have that favourable prognosis as in younger children, this is not proven in the literature. The German BFM group found in their studies a cut-off point at six years. EFS at six years decreased steadily with increased age: one to five years 81%, six to nine years 71%, above nine years 65% [33] . Nachman et al. described similar survival rates for ages 10-15, 16-17, 18-19 , and 20 years (65%) [11] . In T-cell ALL there is a steadily decrease in EFS from five years onwards [34] .
In the CCG-105 trial, patients with ages between 10 and 20 years have an increased risk for relapse of their leukaemia. Using a Berlin-Frankfurt-Munster based protocol the relative event rate was 1.65 in this age group presenting with < 50 x 1O 9 /1 at diagnosis, as compared with younger children. In this randomized trial, in children less than 10 years of age a standard three-drug induction (prednisone, vincristine and asparaginase) and delayed intensification produced an EFS at five years of 77%. Comparison of outcome of patients in the ages 10-15 years versus 16-21 years showed that the older patients have a higher EFS (± 40% versus 20%) [13] . Also in CCG-106, which also included patients with unfavourable presenting features (defined as a WBC > 50 x 1O 9 /1 and FAB-L2 morphology) the EFS rate was significantly lower for patients ^ 10 years as compared with children below 10 years of age (rates of 50 and 71%, respectively). [35] . In the recent data from the UK the higher relapse risk for older ages has been confirmed, however survival in CR is not statistically different [3] .
For patients with ALL with bulky extramedullary disease (predominantly with T-cell immunophenotype) EFS is not influenced by age [36] . This is in line with the description that in T-cell-non-Hodgkin's lymphoma, patients treated with intensive ALL-type therapy had similar EFS at five years (> 10-18 years 94%, < 10 years 89%) [36] . In the study of Shuster et al. the presence of hepatosplenomegaly was related with outcome. However, they noted a decreased prognosis if patients with T-ALL were older. Similar to other reports they found that increasing age is a continuous variable for a worse outcome [15, 34] .
Drugmetabolism
Explanatory for the differences in CR rate and ultimate outcome are not only differences in prognostic factors; also differences in drug resistance may be important.
The data on drug resistance are even more scarce and scattered in literature than the data on clinical presentation and outcome. The data presented here can only be seen as a summary of the most important reports. The in vivo response to induction treatment is generally considered as being one of the most relevant items in the treatment of ALL. Already in this initial phase there are discrepancies between adults and children. In children the combination of vincristin, prednisone and asparaginase gives CR rates > 90%. In adults, however, CR rates of 36%-67% are achieved on vincristine and prednisone; however, they are not affected by asparaginase. Addition of anthracyclines improves CR rate up to 75% [9, 10] . In paediatric studies the use of anthracyclin (adriamycin) during induction is reported to give a better survival [38] . In the German study on ALL the in vivo prednisone response (blasts in a peripheral blood sample <1.0 x 10 9 /l after 6 days of treatment) in children is related with prognosis: EFS (at 6 days) 68%, versus 36% with higher number of blasts after one week prednisone monotherapy. This phenomenon was also seen in children above 5= 10 years [33] . In paediatric Philadelphia+ ALL the in vivo prednisone response is in 35% inadequate, which is significantly different from the 10% inadequate prednisone response in a general ALL study population [39] . Since outcome was correlated with prednisone response, poorer results in the age group > 10 are influenced by this feature. However, as indicated above, the number of Ph+ ALL patients is to low to be the major reason for the poorer results.
The most extensive in vitro data were collected by Pieters et al. They describe a pronounced resistance for prednisone, dexamethasone, asparaginase, idarubicin, daunorubicin, 6-mercaptopurin and vincristine in cells originating from patients over 10 years of age [40] [41] [42] . Hyperdiploidy is related with a favourable response to antimetabolite therapy [41, 43] . At least the low number of hyperdiploid cases and the resulting selection of relative resistant leukaemias is causing the lower outcome in ages > 10 years. The higher numbers of T-ALL cells, which are more resistant to prednisone, asparaginase and vincristine and to a lesser extent for several other drugs is an additional point. However T cells have no higher resistance for thiopurines and teniposide [40] . Also Maung et al. compared adult and childhood leukaemia blasts. Lymphoblasts from adults demonstrated a significant higher degree of in vitro resistance to prednisone. They also demonstrated that age, WBC at diagnosis, sex, cytogenetics and immunophotypes were not associated with in vitro drug sensitivity [44] . However, others have described a decreased accumulation in B-lineage ALL cells of methotrexate and methotrexate-polyglutamates in adult patients (mean age 42.6 years SD ± 15.8) versus paediatric patients (mean age 6.7 years, SD ± 5.5). Also T cells proved to have defective accumulation of (polyglutamated-)MTX [45] .
Conclusions
To conclude, the following remarks can be made. ALL in young patients > 10 years of age has proven to be curable in most cases using intensive treatment protocols. There are several prognostic factors related to a worse outcome as compared to the younger age groups, e.g., higher WBC, more T-cell immunophenotypes (especially the pro-T-cell phenotypes), lower TEL/AML1 positive cases, higher number of t(l; 19), higher frequency of Phi+, increased drug resistance. However, age itself probably still is the most important independent risk factor. Regarding the limited reports on drug resistance only some remarks can be made regarding (future) treatment. For example, it is doubtful whether asparaginase is an important drug for adolescent ALL. Anthracyclines have proven their efficacy. Methotrexate is probably less important for the older age groups, especially during maintenance therapy, where 6-mercaptopurin is probably a more important drug. For central nervous system prophylaxis the alternative for methotrexate, i.e., craniospinal irradiation is, however, for these relatively young patients unattractive. Epipodophylotoxins should be considered designing new trials. Although the efficacy of corticosteroids is less in comparison of young children, no physician will probably leave this crucial drug out of the new treatment schemes.
